Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Inhibikase Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get IKT alerts

About Mark Iwicki

Mark Iwicki is recorded as CEO and Board Member at Inhibikase Therapeutics, Inc. (IKT). The newest filing on record that lists Mark Iwicki as CEO and Board Member at Inhibikase Therapeutics, Inc. (IKT) is dated April 30, 2026. Mark Iwicki was last confirmed as Board Member at KALA BIO, Inc. (KALA) in a filing dated December 30, 2025. Earlier roles on record: Board Member at KALA BIO, Inc. (KALA) until December 19, 2025, CEO at KALA BIO, Inc. (KALA) until February 11, 2025 and Board Member at Jade Biosciences, Inc. (JBIO) until April 28, 2025. KALA BIO, Inc. reported in an 8-K filed February 2, 2026 that Mark Iwicki resigned as Class II director, effective December 19, 2025. The same filing states: “Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.” KALA BIO, Inc. reported in an 8-K filed December 29, 2025 that Mark Iwicki resigned as director. The same filing states: “The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.” Jade Biosciences, Inc. reported in an 8-K filed May 1, 2025 that Mark Iwicki resigned as Aerovate's board of directors, effective April 28, 2025. Equibles holds 6 filed executive changes naming Mark Iwicki; each is listed under recent activity with its source filing. The proxy statement of Inhibikase Therapeutics, Inc. reports total compensation of $30,586,007 for Mark Iwicki in fiscal 2025, including a base salary of $624,208. Disclosed compensation is on record for 5 fiscal years. Mark Iwicki has spoken on 10 earnings calls and 1 other investor event across 2 companies, most recently for Inhibikase Therapeutics, Inc. on November 16, 2026. Those appearances were for KALA BIO, Inc. (KALA) and Inhibikase Therapeutics, Inc. (IKT). Inhibikase Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other companies whose calls Mark Iwicki spoke on are classified in the Healthcare sector. Other leadership on record at Inhibikase Therapeutics, Inc. includes Amit Munshi (Chairman and Board Member), Roberto Bellini (Chairman and Board Member), David McIntyre (CFO) and 4 others.

“on December 19, 2025, each of (i) Marjan Farid, M.D. and Andrew I. Koven, who were Class I directors of the Company, (ii) Mark Iwicki and Todd Bazemore were Class II directors of the Company, and (iii) C. Daniel Meyers and Howard B. Rosen, who were Class III directors of the Company (collectively, the "Resigning Directors"), tendered their resignations as directors of the Company, effective immediately following the Annual Meeting and upon approval of the Issuance Proposal and the Share Increase Proposal”
“Each of Messrs. Farid, Koven, Iwicki, Bazemore, Meyers and Rosen's resignations was due to the approval of the Issuance Proposal and the Share Increase Proposal at the Annual Meeting and did not arise or result from any disagreement with the Company on any matters relating to the Company's operations, policies or practices.”
KALA BIO, Inc. Form 8-K, filed February 2, 2026 · Read the filing
“each of Marjan Farid, M.D., Andrew I. Koven, C. Daniel Myers, Todd Bazmore, Mark Iwicki, and Howard B. Rosen tendered on December 19, 2025 a conditional resignation from their positions as director effective immediately after the Company's 2025 Annual Meeting if stockholder approval is obtained at such 2025 Annual Meeting”
“The resignations were not due to any disagreement with the Company on any matter relating to its operations, policies or practices.”
KALA BIO, Inc. Form 8-K, filed December 29, 2025 · Read the filing

Mark Iwicki on recent calls

“We have 28 countries approved and 79 sites up and running. And that's really in the past kind of four to six months. So we're feeling great. We're achieving our internal expectations.”
CEO, Jefferies Global Healthcare Conference ·
“And thank you everyone for joining us this morning. We are entering the second half of 2022 focused on transitioning from a commercial stage company back to our roots as an R&D organization with our efforts targeted on developing novel medicines that can improve the care and treatment of serious eye diseases.”
CEO, KALA BIO, Inc. Q2 FY2022 Earnings Call ·
“We started Kala a number of years ago with the mission to advance the treatment of front and back of the eye diseases by providing patients and physicians with a portfolio of new medicines that are safe, well tolerated and highly effective.”
CEO, KALA BIO, Inc. Q1 FY2022 Earnings Call ·
“Good morning, everyone, and thank you for joining us today to review our fourth quarter and full year 2021 financial results and recent business highlights.”
CEO, KALA BIO, Inc. Q4 FY2021 Earnings Call ·
“Good morning everyone and thank you for joining us today to review our third quarter 2021 financial results and recent business highlights.”
Chairman, KALA BIO, Inc. Q3 FY2021 Earnings Call ·

Affiliation history

Company network

Leadership on record at Inhibikase Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Inhibikase Therapeutics, Inc. (IKT) $624,208 $30,586,007
2025 KALA BIO, Inc. (KALA) $111,866 $906,642
2024 KALA BIO, Inc. (KALA) $709,394 $1,491,187
2023 KALA BIO, Inc. (KALA) $709,394 $8,342,714
2022 KALA BIO, Inc. (KALA) $682,110 $1,868,299
2021 KALA BIO, Inc. (KALA) $643,500 $2,772,056

Recent activity

Show 5 earlier activities